natgillin/translations-raw huggingface dataset:
Additional data are provided from 289 adults enrolled in studies of vaccine candidates for an additional 7 influenza subtypes and from 240 adults and 259 children enrolled in studies of the monovalent 2009 H1N1 pandemic vaccine. 
Dodatni podatki izvirajo od 289 odraslih, vključenih v študije kandidatov za cepiva za dodatnih 7 podtipov gripe in od 240 odraslih in 259 otrok, vključenih v študije monovalentnega pandemskega cepiva 2009 H1N1.
Administration of influenza antiviral agents within two weeks of vaccination may affect the response of the vaccine. 
Uporaba protivirusnih zdravil proti gripi v dveh tednih po cepljenju lahko poslabša odziv na cepivo.
Most hospitalisations were due to gastrointestinal and respiratory tract infections and occurred more than 6 weeks post vaccination. 
Vzrok večine sprejemov v bolnišnico so bile okužbe prebavil in dihal; pojavile so se več kot 6 tednov po cepljenju.
However, in a pandemic situation, your doctor may recommend to give you the vaccine provided that appropriate medical treatement is immediately available in case of an allergic reaction. 
Toda v primeru pandemije vam bo zdravnik morda vseeno priporočil uporabo cepiva, pod pogojem, da je nemudoma na voljo ustrezno zdravljenje za primer alergijske reakcije.
D153-P502 Europe 6 to 35 M 
D153-P502 Evropa 6 do 35 m
M = months Number of study participants for year 1 or year 2 primary efficacy analysis. 
ZDA 15 do 71 m m = mesecev Število preiskovancev v študiji za 1. ali 2. leto primarne analize učinkovitosti.
After declaration in the EU of a pandemic and after implementation of the pandemic vaccine 
Po razglasitvi pandemije v EU in po uvedbi cepljenja s cepivom proti pandemični gripi.
Due to the association of Reye's syndrome with salicylates and wild-type influenza infection, healthcare providers should assess the potential risks of administering the vaccine with the potential benefits in a pandemic situation (see section 4.5). 
Zaradi povezanosti Reyevega sindroma s salicilati in okužbo z divjim tipom gripe morajo zdravniki pretehtati možna tveganja uporabe cepiva v primerjavi z možnimi koristmi v primeru pandemije (glejte poglavje 4.5).
11 to 24 M 1,150 2002-2003 
11 do 24 m 1.150 2002-2003
The adverse reactions reported were similar to those seen with the recommended single dose of T/LAIV and Fluenz Tetra. 
Zabeleženi neželeni učinki so bili podobni tistim, ki so jih opažali s priporočenim enkratnim odmerkom T/LAIV in cepivom Fluenz Tetra.
USA, Europe, Asia/Oceania 
ZDA, Evropa, Azija/Oceanija
Serum samples were available from 7 subjects in Group 3 on Day 28 and from 18 subjects in Group 5 on Day 56. 
Na voljo so bili vzorci seruma 7 preiskovancev v 3. skupini 28. dan in 18 preiskovancev v 5. skupini 56 dan.
T/LAIV's efficacy data in the paediatric population consist of 9 controlled studies comprising over 20,000 infants and toddlers, children and adolescents, conducted during 7 influenza seasons. 
Podatki o učinkovitosti T/LAIV v pediatrični populaciji izvirajo iz 9 kontroliranih študij, ki so skupaj zajele več kot 20.000 dojenčkov, malčkov, otrok in mladostnikov in so bile izvedene v 7 sezonah gripe.
Children less than 12 months 
Otroci, mlajši od 12 mesecev
There are a moderate amount of data from the use of T/LAIV and the seasonal Fluenz Tetra vaccine in pregnant women. 
Obstaja zmerna količina podatkov o uporabi T/LAIV in sezonskega cepiva Fluenz Tetra pri nosečnicah.
No data are available for individuals with significant clinical immunodeficiency. 
Podatkov o osebah s pomembno klinično imunsko pomanjkljivostjo ni.
Children and adolescents from 12 months to less than 18 years of age 0.2 ml (administered as 0.1 ml per nostril). 
Otroci in mladostniki, stari od 12 mesecev do manj kot 18 let 0,2 ml (uporabljeno kot 0,1 ml na nosnico).
Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 12 hours at a temperature not above 25°C. 
Pred uporabo se sme cepivo vzeti iz hladilnika enkrat za največ 12 ur pri temperaturi do 25 ° C. Če cepivo po tem 12-urnem obdobju ni uporabljeno, ga je treba zavreči.
Reduction in culture-confirmed influenza illness relative to placebo. 
Zmanjšanje s kulturo potrjene gripe v primerjavi s placebom.
Number of study participants 
Število udeležencev v študiji
• if you are already taking acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever). 
• če že jemljete acetilsalicilno kislino (zdravilno učinkovino, ki jo vsebujejo številna zdravila proti bolečinam in zdravila za zniževanje visoke telesne temperature).
Number of Vietnam inactivat ed vaccine doses 
Število odmerkov inaktiviranega cepiva Vietnam 2004
5 single-use nasal applicators (0.2 ml each) 
5 nosnikov za enkratno uporabo (vsak 0,2 ml)
Post-marketing data from occasional inadvertent gestational use of the seasonal vaccines offer some reassurance. 
Podatki v obdobju trženja cepiva o občasni naključni uporabi sezonskih cepiv med nosečnostjo, dajejo določeno zagotovilo.
Do not use this vaccine after the expiry date which is stated on the applicator label after the letters EXP. 
Cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki nosnika poleg oznake EXP.
Prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age. 
Preprečevanje gripe v primeru uradno razglašene pandemije pri otrocih in mladostnikih v starosti od 12 mesecev do manj kot 18 let.
Study group 
Študijska skupina
Animal developmental toxicity studies conducted with T/LAIV and Fluenz Tetra do not indicate direct or indirect harmful effects with respect to reproductive toxicity. 
Razvojne študije na živalih, opravljene s T/LAIV in cepivom Fluenz Tetra, ne kažejo neposrednih ali posrednih škodljivih učinkov, kar zadeva toksične vplive na sposobnost razmnoževanja.
Metabolism and nutrition disorders Very common: Decreased appetite 
Presnovne in prehranske motnje Zelo pogosti: zmanjšanje apetita
However, in a pandemic situation, it may be appropriate to give the vaccine, provided that facilities for resuscitation are immediately available in case of need. 
Toda v primeru pandemije je lahko uporaba tega cepiva vseeno primerna pod pogojem, da je nemudoma na voljo vse, kar je potrebno za reanimacijo, če bi bila potrebna.
The rate of wheezing was not increased in T/LAIV recipients 24 months of age and older. 
Delež piskajočega dihanja ni bil večji med prejemniki T/LAIV, starimi 24 mesecev ali več.
In a pandemic situation, healthcare providers need to assess the potential benefits, alternatives, and risks of administering the vaccine to children and adolescents with significant clinical immunodeficiency due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids. 
V primeru pandemije mora zdravnik oceniti morebitne koristi, alternative in tveganja uporabe cepiva za otroke in mladostnike, ki imajo pomembno klinično imunsko pomanjkljivost zaradi bolezni ali imunosupresivnega zdravljenja, na primer zaradi akutne ali kronične levkemije, limfoma, simptomatske okužbe s HIV, pomanjkljivosti celične imunosti ali visokih odmerkov kortikosteroidov.
Table 1 T/LAIV efficacy in placebo controlled paediatric studies 
Preglednica 1 Učinkovitost T/LAIV v pediatričnih študijah, kontroliranih s placebom
Other medicines, other vaccines and Pandemic influenza vaccine H5N1 AstraZeneca Tell your doctor, nurse or pharmacist if the person being vaccinated is taking, has recently taken or might take any other medicines, including medicines that do not require a prescription. 
Druga zdravila, druga cepiva in Cepivo proti pandemski gripi H5N1 AstraZeneca Zdravnika, medicinsko sestro ali farmacevta morate obvestiti, če oseba, ki bo cepljena, jemlje, je pred kratkim jemala ali pa bo morda začela jemati katero koli drugo zdravilo, vključno z zdravili, za katera ni potreben recept.
The incidence of wheezing within 15 days after vaccination was lower in T/LAIV recipients relative to seasonal inactivated vaccine recipients (19.5% vs. 23.8%, P=0.02). 
Pojavnost piskajočega dihanja v 15 dneh po cepljenju je bila manjša med prejemniki T/LAIV kot med prejemniki sezonskega inaktiviranega cepiva (19,5 % v primerjavi s 23,8 %, p = 0,02).
The MAH should submit the final results of this study. 
Imetnik dovoljenja za promet z zdravilom mora predložiti končne rezultate te študije.
In circumstances where contact with severely immunocompromised individuals is unavoidable, the potential risk of transmission of the influenza vaccine virus should be weighed against the risk of acquiring and transmitting wild-type influenza virus. 
Če se stiku z imunsko zelo oslabelimi osebami ni mogoče izogniti, je treba možno tveganje za prenos virusa gripe iz cepiva pretehtati v primerjavi s tveganjem za okužbo z divjim tipom virusa gripe in njegovim prenosom.
PACK SIZE OF 10 SINGLE-USE NASAL APPLICATORS (IN TRAYS) 
VELIKOST PAKIRANJA Z 10 NOSNIKI ZA ENKRATNO UPORABO (V PLADNJIH)
All children will receive a second, follow-up dose after an interval of at least 4 weeks. 
Vsi otroci bodo po 4-tedenskem presledku dobili še drugi, nadaljevalni odmerek.
The safety of seasonal live attenuated influenza vaccine (LAIV) in children with severe asthma and active wheezing has not been adequately studied. 
Varnost sezonskega cepiva z živim oslabljenim virusom gripe (LAIV - Live Attenuated Influenza Vaccine) pri otrocih s hudo astmo in aktivnim piskajočim dihanjem ni dovolj raziskana.
P/LAIV priming dose 
Primarni odmerek P/LAIV
• It is recommended that Pandemic influenza vaccine H5N1 AstraZeneca is not given at the same time as influenza-specific antiviral medicines such as oseltamivir and zanamivir. 
• Priporočljivo je, da se Cepiva proti pandemski gripi H5N1 AstraZeneca ne uporabi hkrati s protivirusnimi zdravili, specifičnimi za gripo, kakršni sta na primer oseltamivir in zanamivir.
Post-marketing experience with seasonal T/LAIV Very rare reports of Guillain-Barré syndrome and exacerbation of symptoms of Leigh syndrome (mitochondrial encephalomyopathy) have also been observed. 
Izkušnje s sezonskim cepivom T/LAIV iz obdobja po prihodu cepiva na trg Zabeležili so zelo redke primere Guillain-Barréjevega sindroma in poslabšanja simptomov Leighovega sindroma (mitohondrijska encefalomiopatija).
In a surveillance study conducted by the US CDC (Griffin, et al, 2011) the effectiveness of the H1N1 pandemic LAIV vaccine in children 2 through 9 years of age was estimated at 81.9% (95% CI:13.6, 
V spremljevalni študiji, ki so jo izvedli CDC ZDA (Griffin, et al. 2011), je bila ocenjena učinkovitost pandemskega cepiva LAIV H1N1 pri otrocih od 2. do 9. leta 81,9 % (95 % IZ:
The European Medicines Agency will review new information on this medicines at least every year and this leaflet will be updated as necessary. 
Evropska agencija za zdravila bo vsaj enkrat letno ponovno pregledala nove podatke o tem zdravilu.
The study enrolled 69 subjects in 5 groups: Group 1 enrolled 11 subjects who had previously received 2 doses of the A/Vietnam/1203/2004 H5N1 pandemic live attenuated influenza vaccine (P/LAIV) in 2006-2007; Group 2 enrolled 10 subjects who had previously received 2 doses of the A/Hong Kong/213/2003 H5N1 P/LAIV in 2007; Group 3 enrolled 8 subjects who had previously received 2 doses of the A/British Columbia/CN-6/2004 H7N3 P/LAIV in 2010 (as a P/LAIV control group); Groups 4 and 5 each enrolled 20 subjects who had not been previously vaccinated with LAIV and were influenza H5 naïve. 
Študija je zajela 69 oseb v 5 skupinah: 1. skupina je vključila 11 preiskovancev, ki so predhodno dobili 2 odmerka pandemskega oslabljenega cepiva proti gripi A/Vietnam/1203/2004 H5N1 (P/LAIV) v letih 2006-2007, 2. skupina je vključila 10 preiskovancev, ki so predhodno dobili 2 odmerka A/Hong Kong/213/2003 H5N1 P/LAIV leta 2007, 3. skupina je vključila 8 preiskovancev, ki so predhodno dobili 2 odmerka A/British Columbia/CN6/2004 H7N3 P/LAIV leta 2010 (kot kontrolno skupino P/LAIV), 4. in 5. skupina pa sta vsaka vključili 20 preiskovancev, ki predhodno niso bili cepljeni z LAIV in so bili naivni za gripo H5.
Europe, Asia/ Oceania, Latin America 
Evropa, Azija/ Oceanija, Latinska Amerika
Clinical studies have evaluated the incidence of adverse reactions in 59 adults from 18 to 49 years of age receiving at least one dose of Pandemic influenza vaccine H5N1 AstraZeneca. 
V kliničnih študijah so ocenili pojavnost neželenih učinkov pri 59 odraslih, starih od 18 do 49 let, ki so prejeli vsaj en odmerek Cepiva proti pandemski gripi H5N1 AstraZeneca.
Uncommon: Hypersensitivity reactions (including facial oedema, urticaria and very rare anaphylactic reactions) 
Občasni: preobčutljivostne reakcije (vključno z edemom obraza, urtikarijo in zelo redkimi anafilaktičnimi reakcijami)
Seroresponse rates were slightly higher among subjects who were seronegative at baseline. 
Deleži seropozitivnosti so bili nekoliko večji med preiskovanci, ki so bili izhodiščno seronegativni.
The European Medicines Agency has deferred the obligation to submit the results of studies with Pandemic influenza vaccine H5N1 AstraZeneca in one or more subsets of the paediatric population in prevention of influenza infection. 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij s Cepivom proti pandemski gripi H5N1 AstraZeneca za eno ali več podskupin pediatrične populacije za preprečevanje okužbe z gripo.
The primary circulating strain was antigenically dissimilar from the H3N2 strain represented in the vaccine; efficacy against the mismatched A/H3N2 strain was 85.9% (95% CI: 75.3, 91.9). 
Primarni sev v obtoku se je antigensko razlikoval od seva H3N2 v cepivu; učinkovitost proti neujemajočemu se sevu A/H3N2 je bila 85,9 % (95 % IZ: 75,3, 91,9).
Reduction in culture-confirmed influenza illness relative to injectable influenza vaccine. 
Zmanjšanje s kulturo potrjene gripe v primerjavi s cepivom proti gripi za injiciranje.
P/LAIV H5N1 vaccine 
Cepivo P/LAIV H5N1
12 to 35 M 
12 do 35 m
6 to 35 M 
6 do 35 m
FFU per 0.2 ml dose 
enot FFU na 0,2-ml odmerek
H5N1 Hong Kong 
H5N1 Hong Kong brez brez
Data for Group 3, subjects initially vaccinated with an H7N3 P/LAIV are not shown. 
Podatki za 3. skupino (preiskovanci, uvodoma cepljeni s P/LAIV H7N3) niso prikazani.
In clinical studies, the safety profile of Pandemic influenza vaccine H5N1 AstraZeneca was comparable to the safety profile of the seasonal vaccines T/LAIV and Fluenz Tetra (see section 5.1 for more information). 
V kliničnih študijah je bil varnostni profil Cepiva proti pandemski gripi H5N1 AstraZeneca primerljive z varnostnim profilom sezonskih cepiv T/LAIV in Fluenz Tetra (za več informacij glejte poglavje 5.1).
Immunocompromised 
Imunsko oslabeli
Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event or hypersensitivity event following administration of the vaccine. 
Vedno morata biti na voljo ustrezna medicinska oskrba in nadzor za primer, da se po dajanju cepiva pojavi anafilaktična ali preobčutljivostna reakcija.
Use of salicylates in children and adolescents for 4 weeks after vaccination should be avoided unless medically indicated as Reye's syndrome has been reported following the use of salicylates during wild-type influenza infection. 
Pri otrocih in mladostnikih se 4 tedne po cepljenju ne sme uporabljati salicilatov (razen če so medicinsko indicirani), ker je bil po uporabi salicilatov med okužbo z divjim tipom gripe opisan Reyev sindrom.
In a study (D153-P515) of children 6 to 17 years of age with asthma (seasonal T/LAIV: n=1,114, seasonal injectable influenza vaccine: n=1,115), there were no significant differences between treatment groups in the incidence of asthma exacerbations, mean peak expiratory flow rate, asthma symptom scores, or night-time awakening scores. 
V študiji (D153-P515), ki je zajela otroke z astmo, stare od 6 do 12 let, (sezonsko cepivo T/LAIV: n = 1.114, sezonsko cepivo proti gripi za injiciranje: n = 1.115), med skupinama niso ugotovili značilnih razlik v pojavnosti poslabšanj astme, povprečnem največjem ekspiracijskem pretoku zraka, ocenah simptomov astme in ocenah prebujanja ponoči.
Table 3 Serum microneutralization (MN) and haemagglutination inhibition (HAI) assay antibody responses on Days 28 and 56 following administration of an inactivated H5N1 vaccine 
Preglednica 3 Serumski protitelesni odzivi mikronevtralizacije (MN) in preskus inhibicije hemaglutinacije (HAI) 28. in 56. dan po uporabi inaktiviranega cepiva H5N1
Although safety in children and adolescents with mild to moderate asthma has been established for T/LAIV, data in children with other pulmonary diseases or with chronic cardiovascular, metabolic or renal diseases are limited. 
Varnost in učinkovitost T/LAIV sta sicer ugotovljeni pri mladostnikih z blago do zmerno astmo, a podatkov o otrocih z drugimi boleznimi pljuč ali s kroničnimi srčno-žilnimi, presnovnimi ali ledvičnimi boleznimi je malo.
Children and adolescents under 18 years of age receiving salicylate therapy should avoid vaccination with Pandemic influenza vaccine H5N1 AstraZeneca (see section 4.4). 
Otroci in mladostniki, mlajši od 18 let, ki prejemajo zdravljenje s salicilati, ne smejo biti cepljeni s Cepivom proti pandemski gripi H5N1 AstraZeneca (glejte poglavje 4.4).
For placebo recipients regardless of baseline serostatus, seroresponse rate was 6.3% on Days 15 and 29 and 14.5% on Day 57. 
Med prejemniki placeba (ne glede na izhodiščni serološki status) je bil delež serološkega odziva 15. in 29. dan 6,3 % in 57. dan 14,5 %.
In a study (AV010) of children and adolescents 9 to 17 years of age with moderate to severe asthma (seasonal T/LAIV: n=24, placebo: n=24), the primary safety criterion, change in percent predicted forced expiratory volume in 1 second (FEV1) measured before and after vaccination, did not differ between treatment arms. 
V študiji (AV010) otrok in mladostnikov, starih od 9 do 17 let, z zmerno do hudo astmo (sezonsko cepivo T/LAIV: n = 24, placebo: n = 24) se primarno merilo varnosti - odstotna sprememba predvidenega največjega ekspiracijskega volumna v 1 sekundi (FEV1) - izmerjeno pred cepljenjem in po njem med terapevtskima skupinama ni razlikovalo.
The suspension is colourless to pale yellow, clear to slightly cloudy. 
Suspenzija je brezbarvna do bledorumena in bistra do rahlo motna.
In more than 300 case reports in the AstraZeneca safety database of vaccine administration in pregnant women, no unusual patterns of pregnancy complications or foetal outcomes were observed. 
V več kot 300 poročanih primerih v varnostni bazi podatkov družbe AstraZeneca ni bilo mogoče opaziti neobičajnih zapletov v nosečnosti ali izidov za plod pri uporabi cepiva pri nosečnicah.
In addition, studies conducted with AstraZeneca's 2009 H1N1 pandemic LAIV and seasonal T/LAIV vaccine are also considered supportive because all these vaccines are manufactured using the same process, administered through the same route, and studied primarily in naïve individuals. 
Poleg tega veljajo kot podpora tudi študije z AstraZeneca cepivoma (pandemskim cepivom LAIV 2009 H1N1 in sezonskim cepivom T/LAIV), ker so vsa tri cepiva izdelana po enakem postopku, je pot uporabe enaka in so v prvi vrsti raziskana pri predhodno neizpostavljenih osebah.
The most common adverse reactions observed in clinical studies conducted with the Pandemic influenza vaccine H5N1 AstraZeneca in healthy adults was headache (25.4%) and upper respiratory infection (10.2%). 
Najpogostejša neželena učinka v kliničnih študijah z Cepivom proti pandemski gripi H5N1 AstraZeneca pri zdravih odraslih sta bila glavobol (25,4 %) in okužba zgornjih dihal (10,2 %).
TCID50 of the vaccine intranasally in isolation, with 16 of those subjects receiving a second dose 4-8 weeks later. 
TCID50 cepiva intranazalno izolirano; 16 od teh preiskovancev je od 4 do 8 tednov pozneje prejelo drugi odmerek.
Clinical study CIR 277 assessed whether prior recipients of pandemic live attenuated influenza H5N1 vaccines were primed or established long-lasting immunity that could be detected following the subsequent administration of an inactivated H5N1 vaccine. 
Klinična študija CIR 277 je ocenila, ali so predhodni prejemniki pandemskih živih oslabljenih cepiv proti gripi H5N1 dosegli osnovni odziv (priming) oz. dolgotrajno imunost, ki bi jo bilo mogoče zaznati po nadaljnji uporabi inaktiviranega cepiva H5N1.
Study number 
Številka študije
Similar responses were seen with P/LAIV H7N7- and H7N9-primed subjects who developed vigorous antibody responses to the corresponding wild-type viruses upon subsequent exposure to the inactivated vaccine from the same subtype. 
Podobne odzive so ugotovili pri preiskovancih, primarno cepljenih s P/LAIV H7N7 in H7N9, ki se jim je razvil intenziven odziv protiteles proti ustreznim divjim tipom virusov po poznejši izpostavljenosti inaktiviranemu cepivu istega podtipa.
PACK SIZE OF 5 SINGLE-USE NASAL APPLICATORS 
VELIKOST PAKIRANJA S 5 NOSNIKI ZA ENKRATNO UPORABO
In a pandemic situation, the use of Pandemic influenza vaccine H5N1 AstraZeneca in mildly to moderately immunosuppressed individuals may be considered after weighing the anticipated benefits against the potential risks for the individual. 
V primeru pandemije pride uporaba Cepiva proti pandemski gripi H5N1 AstraZeneca pri blago do zmerno imunosuprimiranih osebah v poštev po pretehtanju predvidenih koristi v primerjavi z možnimi tveganji za posameznika.
Pandemic influenza vaccine H5N1 AstraZeneca is not indicated for use in infants younger than 12 months of age (see section 4.2). 
Cepivo proti pandemski gripi H5N1 AstraZeneca ni indicirano za uporabo pri otrocih, mlajših od 12 mesecev (glejte poglavje 4.2).
This vaccine is presented as a nasal spray suspension in a single-use nasal applicator (0.2 ml) in a pack size of 10. 
To cepivo je na voljo kot suspenzija v pršilu za nos v nosniku za enkratno uporabo (0,2 ml) v pakiranjih po 10 nosnikov.
Of the P/LAIV-naïve subjects, only 10% had ≥4-fold rises by Day 
Med P/LAIV naivnimi preiskovanci jih je imelo do 7. dne ≥ 4-kraten porast le 10 %.
Pandemic influenza vaccine H5N1 AstraZeneca should not be used in infants below 12 months of age because of safety concerns regarding increased rates of hospitalisation and wheezing in this population (see section 4.8). 
Cepiva proti pandemski gripi H5N1 AstraZeneca se ne sme uporabljati pri dojenčkih, mlajših od 12 mesecev zaradi pomislekov glede varnosti zaradi večjega deleža sprejemov v bolnišnico in piskajočega dihanja pri tej populaciji (glejte poglavje 4.8).
Pandemic influenza vaccine H5N1 AstraZeneca will be administered under the supervision of a doctor, nurse or pharmacist. 
Cepivo proti pandemski gripi H5N1 AstraZeneca boste dobili pod nadzorstvom zdravnika, medicinske sestre ali farmacevta.
The co-administration of Pandemic influenza vaccine H5N1 AstraZeneca with inactivated vaccines or with the seasonal vaccine Fluenz Tetra has not been studied. 
Sočasna uporaba Cepiva proti pandemski gripi H5N1 AstraZeneca z inaktiviranimi cepivi ali s sezonskim cepivom Fluenz Tetra ni raziskana.
For the H7N7 P/LAIV, strong serum antibody responses were detected by both MN and HAI in 9 of 13 individuals, with peak titers achieved by Day 14. 
Za P/LAIV H7N7 so ugotovili močan odziv protiteles v serumu tako z MN kot s HAI pri 9 od 13 oseb; največji titri so bili doseženi do 14. dne.
This section describes the clinical experience observed in three pivotal studies conducted with the Pandemic influenza vaccine H5N1 AstraZeneca in adults. 
To poglavje opisuje klinične izkušnje v treh ključnih študijah s Cepivom proti pandemski gripi H5N1 AstraZeneca pri odraslih.
Caution is needed when administering this vaccine to individuals with a known hypersensitivity (other than anaphylactic reaction) to the active substance, or to any of the excipients listed in section 6.1, or to trace residues (gentamicin, eggs or egg proteins, ovalbumin). 
Previdnost je potrebna pri uporabi tega cepiva pri osebah z znano preobčutljivostjo (razen anafilaktične reakcije) na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1, ali ostanke v sledeh (gentamicin, jajca ali jajčne beljakovine, ovalbumin).